Article Sidebar

Submitted
Apr 8, 2026
Accepted
May 19, 2026
Published
Jun 20, 2026
Download
pdf
Statistic
Read Counter : 0 Download : 0

Downloads

Download data is not yet available.

Main Article Content

Abstract

Background:


Multi Drug Resistance Tuberculosis (MDR-TB) treatment caused side effects such as hepatotoxicity and acute kidney injury (AKI).  Monitoring liver and kidney function in patients during treatment is crucial to prevent complication.


Methods: A retrospective study of 19 patients confirmed MDR-TB in the period 2022-2025. Liver function test (transaminase enzymes and bilirubin) and kidney function test (urea and creatinine) during the first three month of treatment were analyzed.


Results: Statistically, there was no difference in all parameters (p>0.05). Increases in total bilirubin, SGOT, SGPT levels occurred in the third month of TB treatment. While urea and creatinine levels increased in the second and third months.


Conclusion: Monitoring of liver and kidney function during MDR-TB treatment is necessary to monitor patient condition.

Keywords

Multi Drug Resistance Tuberculosis Liver function Kidney Function

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

How to Cite
Putri, W. R., Widyastuti, H., Cahyani, D. I., & Fajar, W. O. H. (2026). THE LIVER FUNCTION TEST (TRANSAMINASE ENZYMES AND BILIRUBIN) AND THE KIDNEY FUNCTION TESTS (UREA, CREATININE) ANALYSIS IN MDR-TB DURING TREATMENT . INDONESIAN JOURNAL OF HEALTH SCIENCES RESEARCH AND DEVELOPMENT (IJHSRD), 8(1), 109–114. https://doi.org/10.36566/ijhsrd/Vol8.Iss1/370

References

  1. 1. World Health Organization. 2024 Global Tuberculosis (TB) Report. 2024. 8 p.
  2. 2. Gao W, Wang W, Li J, Gao Y, Zhang S, Lei H, et al. Drug-resistance characteristics, genetic diversity, and transmission dynamics of multidrug-resistant or rifampicin-resistant Mycobacterium tuberculosis from 2019 to 2021 in Sichuan, China. Antimicrob Resist Infect Control. 2024;13(1).
  3. 3. Song HW, Tian JH, Song HP, Guo SJ, Lin YH, Pan JS. Tracking multidrug resistant tuberculosis: a 30-year analysis of global, regional, and national trends. Front Public Heal. 2024;12(1).
  4. 4. Omoteso OA, Fadaka AO, Walker RB, Khamanga SM. Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment. Microorganisms. 2025;13(4):1–42.
  5. 5. Chandra B, Fikriana R, Nurbadriyah WD. Faktor Risiko pada Peningkatan Kasus Multidrug-Resistant Tuberculosis ( MDR-TB ) di Indonesia : Tinjauan Literatur. J Univ Muhammadiyah Surabaya. 2025;10(1):159–67.
  6. 6. Xi Y, Zhang W, Qiao RJ, Tang J. Risk factors for multidrug-resistant tuberculosis: A worldwide systematic review and meta-analysis. PLoS One. 2022;17(6 June):1–15.
  7. 7. Muhammad Gugun A, Suryanto S, Ranti Ayuningtyas DN. The Effect of Initial Anti-tuberculosis Drug Therapy on Transminase Enzymes. Cerdika J Ilm Indones. 2024;4(03):214–21.
  8. 8. Muda I, Adam MF, Saputra R, Muhyi A, Noprianto D, Aminuddin M. Association of Multidrug-Resistant Tuberculosis (MDR-TB) Patients on Profile of Liver and Kidney Function. J Kesehat Pasak Bumi Kalimantan. 2023;5(2):139.
  9. 9. Osorio-chávez JS, González VP, Ferraz-amaro I, Castañeda S, Manuel J, Martínez C, et al. Hepatotoxicity Risk of Isoniazid in Patients with Autoimmune Rheumatic Diseases and Prior Liver Injury Due to Disease-Modifying Antirheumatic Drugs : A Single-Center Experience and Literature Review. 2026;1–13.
  10. 10. Sharma K, Basith KMA, Subramanian S, Chinnakali P, Rajaram M, Basu S, et al. Abnormal Liver Function at the Time of Tuberculosis Diagnosis in South India. 2026;
  11. 11. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2016 Oct;63(7):853–67.
  12. 12. Aprianto, Sudarsono TA, Pratiwi D, Wardani K. Comparison of Ureum and Creatinine Levels Pulmonary Tuberculosis in. J Ilmu dan Teknol Kesehat. 2022;9(2).
  13. 13. Saito N, Yoshii Y, Kaneko Y, Nakashima A, Horikiri T, Saito Z, et al. Impact of renal function-based anti- tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease. 2019;1–8.
  14. 14. Park S, Kim HW, Lee EG, Park Y, Jung SS, Woo J, et al. BMC Infectious Diseases Article in Press Association between reduced kidney function and tuberculosis treatment outcomes. 2026.